Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4808-4812

  Offner, Fritz ^a   Krcmery, Vladimir ^e   Boogaerts, Marc ^b   Doyen, Chantal ^c   Engelhard, Dan ^f   Ribaud, Patricia ^g   Cordonnier, Catherine ⁱ   De Pauw, Ben ^l   Durrant, Simon ⁿ   Marie, Jean Pierre ^h   Moreau, Philippe ^j   Guiot, Harry ^m   Samonis, George ^o   Sylvester, Richard ^d   Herbrecht, Raoul ^k  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d EORTC DATA CENTER   (Belgium)

^e St Elisabeth Cancer Institute   (Slovakia)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g SAINT LOUIS HOSPITAL   (France)

^h HÔTEL DIEU   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j HÔTEL DIEU   (France)

^k HÔPITAL DE HAUTEPIERRE   (France)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^o UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIHISTAMINIC AGENT; LIPOSOME; NYSTATIN; PARACETAMOL;

AGED; ANAEROBIC INFECTION; ANEMIA; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLOSTOMY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG ACTIVITY; DRUG INFUSION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FEMALE; FEVER; FREQUENCY ANALYSIS; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOTENSION; INFECTIOUS PNEUMONIA; INJECTION PAIN; KIDNEY FUNCTION; LIVER TOXICITY; LOBECTOMY; LUNG INSUFFICIENCY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OBSERVATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REFRACTORY PERIOD; SALVAGE THERAPY; SHIVERING; SPECIES INVASION; TACHYCARDIA; THROMBOCYTOPENIA; VENTILATOR; VOMITING;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; CAUSE OF DEATH; CHILD; DRUG RESISTANCE, FUNGAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; NEUTROPENIA; NYSTATIN; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME;

EID: 9644272511     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4808-4812.2004     Document Type: Article

References (26)

1. Arikan, S., L. Ostrosky-Zeichner, M. Lozano-Chiu, V. Paetznick, D. Gordon, T. Wallace, and J. H. Rex. 2002. In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J. Clin. Microbiol. 40:1406-1412.
2. Arikan, S., and J. H. Rex. 2001. Nystatin LF (Aronex/Abbott). Curr. Opin. Investig. Drugs 2:488-495.
3. Ascioglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, and T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14.
4. Carrillo-Munoz, A. J., G. Quindos, C. Tur, M. T. Ruesga, Y. Miranda, O. del Valle, P. A. Cossum, and T. L. Wallace. 1999. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J. Antimicrob. Chemother. 44:397-401.
5. Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23:608-615.
6. Denning, D. W., P. Riband, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
7. Denning, D. W., and P. Warn. 1999. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob. Agents Chemother. 43:2592-2599.
8. Groll, A. H., C. E. Gonzalez, N. Giri, K. Kligys, W. Love, J. Peter, E. Feuerstein, J. Bacher, S. C. Piscitelli, and T. J. Walsh. 1999. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J. Antimicrob. Chemother. 43:95-103.
9. Groll, A. H., D. Mickiene, K. Werner, R. Petraitiene, V. Petraitis, M. Calendario, A. Field-Ridley, J. Crisp, S. C. Piscitelli, and T. J. Walsh. 2000. Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits. Antimicrob. Agents Chemother. 44:950-957.
10. Groll, A. H., V. Petraitis, R. Petraitiene, A. Field-Ridley, M. Calendario, J. Bacher, S. C. Piscitelli, and T. J. Walsh. 1999. Safety and efficacy of multi-lamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 43:2463-2467.
11. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
12. Herbrecht, R., V. Letscher, E. Andres, and A. Cavalier. 1999. Safety and efficacy of amphotericin B colloidal dispersion. An overview. Chemotherapy 45:67-76.
13. Johnson, E. M., J. O. Ojwang, A. Szekely, T. L. Wallace, and D. W. Warnock. 1998. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob. Agents Chemother. 42:1412-1416.
14. Krupova, Y., M. Mistrik, E. Bojtarova, D. Sejnova, I. Ilavska, and V. Krcmery, Jr. 2001. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients. Support. Care Cancer 9:209-210.
15. Leenders, A. C., S. Daenen, R. L. Jansen, W. C. Hop, B. Lowenberg, P. W. Wijermans, J. Cornelissen, R. Herbrecht, H. van der Lelie, H. C. Hoogsteden, H. A. Verbrugh, and S. de Marie. 1998. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol. 103:205-212.
16. Lin, S. J., J. Schranz, and S. M. Teutsch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32:358-366.
17. Maertens, J., I. Raad, C. A. Sable, A. Ngai, R. Berman, T. F. Patterson, D. Denning, and T. Walsh. 2002. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulations, or azoles, abstr. J-1103, p. 371. Program Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
18. Mehta, R. T., R. L. Hopfer, L. A. Gunner, R. L. Juliano, and G. Lopez-Berestein. 1987. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 31:1897-1900.
19. Mehta, R. T., R. L. Hopfer, T. McQueen, R. L. Juliano, and G. Lopez-Berestein. 1987. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. 31:1901-1903.
20. Mileshkin, L., M. Slavin, J. F. Seymour, and A. McKenzie. 2001. Successful treatment of rhinocerebral zygomycosis using liposomal nystatin. Leuk. Lymphoma 42:1119-1123.
21. Mills, W., R. Chopra, D. C. Linch, and A. H. Goldstone. 1994. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br. J. Haematol. 86:754-760.
22. Oakley, K. L., C. B. Moore, and D. W. Denning. 1999. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob. Agents Chemother. 43:1264-1266.
23. Powles, R., S. Mawhorter, and T. Williams. 1999. Liposomal nystatin versus amphotericin B in empiric treatment of presumed fungal infection in neutropenic patients, abstr. LB-4, p. 14. Program Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
24. Stevens, D. A., V. L. Ran, M. A. Judson, V. A. Morrison, S. Dummer, D. W. Denning, J. E. Bennett, T. J. Walsh, T. F. Patterson, G. A. Pankey, et al. 2000. Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 30:696-709.
25. Walsh, T. J., J. L. Goodman, P. Pappas, I. Bekersky, D. N. Buell, M. Roden, J. Barrett, and E. J. Anaissie. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45:3487-3496.
26. Williams, A. H., and J. E. Moore, on behalf of a multicenter Nyotran study group. 1999. Multicenter study to evaluate the safety and efficacy of various doses of liposome-encapsulated nystatin in neutropenic patients with candidemia, abstr. 1420, p. 567. Program Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.